TLR9 and colorectal cancer: We hypothesize that combining CD47 blockade with therapies that further reduce myeloid immunosuppression, a key mediator of immunotherapy resistance in MSS colorectal cancer (14, 15), such as KRAS inhibitor, STING agonist, TLR9 agonist, GM-CSF, or inflammasome modulation, could be effective (76–80).